On-line hemodiafiltration in the large RISCAVID study

Contributions to Nephrology

Volumn 175, Issue , 2011, Pages 117-128

  Panichi, Vincenzo ^a   Tetta, Ciro ^b  

^a Versilia Hospital   (Italy)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; HEMODIAFILTRATION; HUMAN; ITALY; KIDNEY DISEASE; MORTALITY; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

CHRONIC DISEASE; HEMODIAFILTRATION; HUMANS; ITALY; KIDNEY DISEASES; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84855803106     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000333295     Document Type: Article

References (44)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002;3:187-197.
2. US Renal Data System: Excerpts from the USRDS 1997 annual data report. Am J Kidney Dis 1997;30:S1-S195.
3. Parfey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-1615. (Pubitemid 29297538)
4. Stenvinkel P, Heinburger O, Paultre F, et al: Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911. (Pubitemid 29197978)
5. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005(suppl 1):S83-S88. (Pubitemid 41725091)
6. Schouten WEM, Grooteman MPC, van Houte AJ, et al: Effects of dialysers and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000;15:379-384. (Pubitemid 30116473)
7. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS: Beyond genetics: Epigenetic code in chronic kidney disease. Kidney Int 2011;79:23-32.
8. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
9. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Wilson PW, D'Agostino RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003;107:1486-1491. (Pubitemid 36378485)
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979. (Pubitemid 27152782)
11. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-424. (Pubitemid 24247397)
12. Lagrand WK, Visser CA, Hermens WT, Niesssen HW, Verheught FW, Wolbink J, Hack CE: C-reactive protein as a cardiovascular risk: More than an epiphenomenon? Circulation 1999;100:96-102. (Pubitemid 29297946)
13. Bhatt DL, Topol EJ: Need to test the arterial Inflammation hypothesis. Circulation 2002;106:136-140. (Pubitemid 34747454)
14. Stenvinkel P: Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif 2001;19:143-151. (Pubitemid 32041345)
15. Kaysen GA: Inflammation: Cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol 2004;24:431-436. (Pubitemid 39361048)
16. Stenvinkel P, Heinburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911. (Pubitemid 29197978)
17. Panichi V, Tetta C, Rindi P, Palla R, Lonnemann G: Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. ASAIO J 1998;744:M415-M417. (Pubitemid 28468867)
18. Stenvinkel P, Bárány P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002;17(suppl 5):32-37. (Pubitemid 34823070)
19. Singh AK, Coyne DW, Shapiro W, Rizkala AR: Predictors of the response to treatment in anemic haemodialysis patients with high serum ferritin and low transferring saturation. Kidney Int 2007;71:1163-1171. (Pubitemid 46809141)
20. Bradbury BD, Critchlow CV, Weir MR Stewart R, Krishnan M, Hakim RH: Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent dose and responsiveness in haemodialysis patients. Nephrol Dial Transplant 2009;24:919-925.
21. Bárány P, Divino Filho JC, Bergström J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565-568. (Pubitemid 27155278)
22. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in hemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160. (Pubitemid 38628135)
23. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C, on behalf of the RISCAVID Study Group: Anaemia and resistance to erythropoiesisstimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study. Nephrol Dial Transplant 2011;26:2641-2618.
24. Bingel M, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Human interleukin-1 production during hemodialysis. Nephron 1986;43:161-163. (Pubitemid 16084312)
25. Lonnemann G: When good water goes bad: How it happens, clinical consequences and possible solutions. Blood Purif 2004;22:124-129. (Pubitemid 38142297)
26. Panichi V, Migliori M, De Pietro S, Taccola D, Andreini B, Metelli MR, Giovannini L, Palla R: The link of biocompatibility to cytokine production. Kidney Int 2000;59(suppl 76):96-103.
27. Ronco C: Fluid mechanics and crossfiltration in hollow-fiber hemodialyzers. Contrib Nephrol. Basel, Karger, 2007, vol 158, pp 34-49.
28. Tetta C, Maffei S, Cisterna B, et al: The evolution of biocompatibility: From microinflammation to microvesicles. Hemodialysis. InTech Publishers, 2011, in press.
29. Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, Ramírez R, Tetta C, Rodríguez M, Martín-Malo A, Aljama P: Online hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: A prospective, crossover study. J Am Soc Nephrol 2006;17:2315-2321. (Pubitemid 44141923)
30. Ramirez R, Carracedo J, Merino A, Nogueras S, Alvarez-Lara MA, Rodríguez M, Martin-Malo A, Tetta C, Aljama P: Microinflammation induces endothelial damage in hemodialysis patients: The role of convective transport. Kidney Int 2007;72:108-113. (Pubitemid 47014444)
31. Tetta C, Roy T, Gatti E, Cerutti S: The rise of hemodialysis machines: New technologies in minimizing cardiovascular complications. Expert Rev Cardiovasc Ther 2011;9:155-164.
32. Canaud B, Chenine L, Renaud S, Leray H: Optimal therapeutic conditions for online hemodiafiltration. Contrib Nephrol. Basel, Karger, 2011, vol 168, pp 28-38.
33. Cappelli G, Riccardi M, Perrone S, Bondi M, Ligabue G, Albertazzi A: Water treatment and monitor disinfection. Hemodialysis Int 2006;10(suppl 1):S13-S18. (Pubitemid 43263302)
34. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R, RISCAVID Study Group: Chronic inflammation and mortality in haemodialysis: Effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008;23:2337-2343. (Pubitemid 351957592)
35. Panichi V, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Giust R, Rosati A, Migliori M, Pasquariello A, Panicucci E, Barsotti G, Bellasi A, RISCAVID Study Group: Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: Results from the RISCAVID study. J Nephrol 2010;23:556-562.
36. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093. (Pubitemid 43924275)
37. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis 2004;44(suppl 2):16-21.
38. Regidor DL, Kopple JD, Kovesdy CP, et al: Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
39. Stivelman JC: Refractoriness to recombinant human epoetin (rHuEPO) treatment; in Nissenson AR, Fine RN (eds): Handbook of Dialysis Therapy, ed 4. Philadelphia, Saunders Elsevier, 2008, pp 812-831.
40. National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-S19.
41. Kilpatrick RD, Critchlow CW, Fishbane S, et al: Greater epoetin-a responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-1083.
42. Szczech LA, Barnhart HX, Inrig JK, et al: Secondary analysis of the CHOIR trial epoietin-a dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798.
43. Tentori F, Blayney MJ, Albert JM, et al: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530.
44. Young EW, Albert JM, Satayathum S, et al: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187. (Pubitemid 41623345)